ISC Spółka z Ograniczoną Odpowiedzialnością (KRS 0000730902, NIP 1231397653) is a Polish company, headquartered in Piaseczno, Mazowieckie voivodeship. ISC operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since May 9, 2018. ISC's most recently reported net revenue was 0 PLN for 2024. ISC's operations are currently suspended.
The company is currently suspended
Suspended since May 31, 2025
No reported revenue
The company reported no revenue in any available reporting year. This may indicate a non-operating entity.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - ISC
Identity
- Name
- ISC Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- May 9, 2018
- Registry status as of
- July 7, 2026
- Latest entry
- July 7, 2026
- Founding act
- 19.04.2018 R.
Articles of association history (2)
- April 19, 2018: 19.04.2018 R.
- February 23, 2021: 23.02.2021 R., REP. A NR 1249/2021, KANCELARIA NOTARIALNA W PIASECZNIE, NOTARIUSZ WOJCIECH BREKSA, DOKONANO ZMIANY UMOWY SPÓŁKI POPRZEZ NADANIE JEJ NOWEJ TREŚCI.
Activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. PUŁAWSKA, 45B, 3, 05-500, PIASECZNO, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- PIASECZYŃSKI
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
Risk and payment profile - ISC
Credibility rating
5 / 100
Very poor credibility
Insolvency risk
suspended
Significant formal threat
Closure risk
80
/ 100
Extremely high risk
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
1
1/8 yrs
Board changes
0
0/8 yrs
PKD changes
0
0/8 yrs
Name changes
0
0/8 yrs
Data from 8 years of registry activity.
Credibility history
Payment reliability score from 2018–2024
Current: S (5/100)
Trend: stable (0.0 pts/year)
Spółka jest obecnie zawieszona – działalność operacyjna wstrzymana, wskaźnik wiarygodności odzwierciedla stan przed zawieszeniem.
Trade credit limit history
Standard limit from 2018–2024
Current: 3.2 K PLN
Safe: 554.81 PLN
Operational status - ISC
Founded
May 9, 2018
8 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
PIASECZNO
MAZOWIECKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
60.0 K PLN
600 shares total
Shareholders
3
shareholders
Board
1 person
Filed years
7 years
2018–2024 · profitable: 1/7
Registry entries
23
latest: July 7, 2026
Risk signals
Revenue
0 PLN
2024
Net profit
-436.2 K PLN
2024
Assets
732.9 K PLN
2024
Equity
704.4 K PLN
2024
EBITDA
-74.9 K PLN
2024
Valuation
0 PLN
suspended
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - ISC.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Captor Therapeutics: PLN 36m of cash at 30 September 2025, runway to mid-2026 – clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.
